Jeffrey Stewart
Executive Vice President, Commercial Operations at AbbVie
Thank you, Rick. I'm very pleased with the momentum across our therapeutic portfolio, including the continued progress we are making with new product and recent indication launches
I'll start with our immunology portfolio, which delivered total revenues of $7.2 billion, reflecting growth of 19.2% on an operational basis. Global Humira sales were approximately $5.4 billion, up 8% on an operational basis, with 9.6% growth in the U.S., partially offset by international performance, where revenues were down 7% operationally due to biosimilar competition.
Skyrizi is performing extremely well, well ahead of our expectations. Global revenues were more than $1.2 billion, up 33% on a sequential basis. We continue to advance our leadership position in psoriasis we're Skyrizi's total prescription share of the U.S. biological market has increased to approximately 26%, driven by an in-play share of new and switching patients that is now approaching 50%. We have also achieved in--play market share leadership in 23 key international markets including Japan,, Germany, France, Canada and Australia.
Psoriatic arthritis is also adding significantly to Skyrizi's momentum, where we are now approved in 54 countries. In the U.S. dermatology segment, we're approximately 30% of patients exhibit both skin and joint involvement. Skyrizi is already achieving an in-play patient share of nearly 20%. We have also launched Skyrizi for PsA in rheumatology where we're seeing strong utilization, which is driving accelerated share growth. Our recent launch of Skyrizi for Crohn's disease in the U.S. represents the first new biologic approval in six years for an area where there continues to be considerable unmet need. We believe SKYRIZI represents a highly effective and differentiated treatment option for Crohn's patients, including the potential to provide meaningful levels of endoscopic improvement, with novel and infrequent dosing. Managed care access is expected to ramp strongly for this indication in the coming months.
Turning now to Rinvoq, where we're seeing good momentum across each of the approved indications. Global sales of $592 million were up more than 27% on a sequential basis. Prescriptions in RA remain strong, with a total market share of 5.8% in the U.S. and approximately 6% across key international markets. Rinvoq is now achieving an in-play RA share of approximately 13% in the U.S.
In PsA, Rinvoq continues to see nice uptake, especially in the room segment, with commercial access now equal to RA. We also recently received FDA approval for ankylosing spondylitis and European approval for non-radiographic axial SpA, further expanding Rinvoq's potential across rheumatology. In atopic dermatitis, new patient starts are tracking in-line with our expectations, with Rinvoq's in-play patient share in the mid-teens. Strong commercial access in AD, which is also now equal to RA and PsA is expected to considerably increased paid prescription volume in this highly underpenetrated market over the remainder of the year.
Lastly, our recent launch of Rinvoq for ulcerative colitis in the U.S is progressing well and we recently just received European approval for the same indication. Commercial access in the U.S. is ramping strongly and we are seeing encouraging new patient starts. Physician feedback regarding Rinvoq's approved profile in UC has been favorable, especially given the very high rates of remission and endoscopic improvement demonstrated across our UC development program. The addressable patient population for Rinvoq in UC is substantial, with nearly 50% of patients currently on or having used TNF therapy.
Turning now to hematologic oncology, where total revenues were $1.65 billion, down 7 9% on an operational basis. Imbruvica global revenues were approximately $1.1 billion, down 17.1% and below our expectations. The CLL market continues to remain challenging in the U.S. with new patient starts down double-digits relative to pre-pandemic levels.
Now, as you may recall, our initial 2022 Imbruvica sales guidance contemplated a partial market recovery, which unfortunately we have not yet observed. In fact, the latest data reflects new patient starts in the U.S. were actually down high single-digits versus last year. So based on recent trends, we no longer believe it's prudent to anticipate a meaningful market recovery in CLL over the second half of this year. Therefore, we will be removing this assumption from our 2022 guidance.
In addition, increasing competition from newer therapies, including other BTK inhibitors as well as our own Venclexta also continue to lower Imbruvica share of new patient starts, especially in frontline CLL. Despite this increasing competitive pressure, Imbruvica continues to be the total market share leaders across all lines of therapy in CLL.
Venclexta global sales were $505 million, up 21.2% on an operational basis. In CLL, we continue to see share gains in the U.S. and across all major international markets. We're also seeing continued strong performance in AML. Venclexta is now approved in 80 countries and in many markets is already considered the new standard-of-care for frontline AML patients who are ineligible for intensive chemotherapy. As a result, we are seeing ramping market share throughout the countries where we have launched.
In neuroscience, revenues were more than $1.6 billion, up 15.2% on an operational basis. Vraylar once again delivered strong growth. Sales of $492 million were up 13.9% on an operational basis, reflecting continued share gains in the U.S. atypical anti-psychotic market. Our launch preparations remain well underway in anticipation of our MDD approval in the fourth quarter. This is a potentially large indication that would represent incremental upside to our current projections for Vraylar.
Within migraine, Ubrelvy remains the market leading oral CGRP treatment for acute migraine, with revenue of $185 million, up 30% on a sequential basis. Qulipta continues to increase its leading new to brand share in the U.S. preventative CGRP class, when we consider both paid and bridge volume. We continue to make good progress with expanded commercial access, which will support strong Qulipta sales growth over the remainder of this year. We are also pursuing the commercial approval for Qulipta as a preventative treatment in patients with chronic migraine in the U.S., as well as a new therapy for Europe, potentially further strengthening our competitive product profile and long-term growth opportunity.
Botox Therapeutic is also performing well in chronic migraine, as well as its other indications with total sales of $678 million, up 5% on an operational basis. So overall, I'm pleased with the commercial execution across the therapeutic business our broad portfolio of differentiated therapies and new launches is demonstrating strong revenue growth.
And with that, I'll turn the call over to Tom, for additional comments on our R&D programs, Tom?